Pas de connexion internet — affichage de la version enregistrée de la page.

Soligenix Inc.

USUSD
← Vers le Screener
US:SNGXLSE:0A6I

Soligenix Inc. (LSE:0A6I) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
soligenix.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège Social
PRINCETON, United States
PDG
Christopher J. Schaber
Employés
13
Cotée Depuis
04.03.2021 (LSE:0A6I)
Actions en Circulation
21.77 M au 2026-07-31
1 An: +245.9% · 3 ans: +0.3% · 5 ans: +263.9% (hors divisions d'actions)
DateActionsVariation
31.07.202621.77 Mdivision 1.5:1
01.05.202614.82 M+43.8%émission (dilution)
24.03.202610.31 M+2.2%émission (dilution)
31.10.202510.09 M+135.4%émission (dilution)
07.08.20254.29 M+31.3%émission (dilution)
02.05.20253.26 M+3.4%émission (dilution)
14.03.20253.16 M+25.7%émission (dilution)
01.11.20242.51 M+10.0%émission (dilution)
02.08.20242.28 M−85.6%rachat
03.05.202415.8 Mdivision 1.5:1
08.03.202410.52 M+1.4%émission (dilution)
06.11.202310.38 M+5.5%émission (dilution)
14.08.20239.84 M+21.3%émission (dilution)
09.05.20238.12 M+177.5%émission (dilution)
24.03.20232.92 Mregroupement 1:15
Nombre d'actions selon les rapports de la société. Une division est détectée par un saut du nombre d'un multiple entier.
Flottant
21.66 M
Capitalisation Boursière
7.91 M USD
Initiés
4.59%
Investisseurs Institutionnels
6.72%
Secteur d'Activité (SIC)
Pharmaceutical Preparations
P/E
perte
FCF
−10.3 M USD
Dette
0 USD
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksSNGX principaleUSD0.3517 -3.27%actions ordinaires
LSE London Stock Exchange0A6I IOBUSD0.36 +0.00%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
Citadel Advisors Llc0.96%209 5072026-06-30
Jane Street Group, LLC0.95%207 4922026-06-30
Xtx Topco Ltd0.72%157 1192026-06-30
Geode Capital Management…0.55%120 2672026-06-30
Vanguard Capital Managem…0.37%81 0052026-06-30
VANGUARD INDEX FUNDS-Van…0.37%81 0052026-06-30
Fidelity Concord Street…0.35%76 1762026-07-31
Virtu Financial LLC0.28%60 9032026-06-30
Vanguard Fiduciary Trust…0.25%53 9142026-06-30
Northern Trust Corporati…0.17%38 0462026-06-30
SCHABER CHRISTOPHER J (C…≈0.07%15 5112025-10-02
Fidelity Concord Street…0.07%14 4592026-07-31
Fidelity Concord Street…0.04%8 0542026-07-31
Morgan Stanley0.02%3 5922026-06-30
Jones Financial Companie…0.01%1 2362026-06-30